Get started
Author

Esranur Aydın

Observed name: Esranur Aydin
Institution: Istinye University
ORCID: 0000-0001-7850-0177
Observed ORCID: 0000-0001-7850-0177
OpenAlex ID: A5071414864
Cytotoxic Activity and Docking Studies of 2-arenoxybenzaldehyde N-acyl Hydrazone and 1,3,4-Oxadiazole Derivatives against Various Cancer Cell Lines
2022 · Esranur Aydın, Ahmet Mesut Şentürk, et al. · Molecules · 19
Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview
2023 · Eylül Özgü, Esranur Aydin, et al. · JCO Precision Oncology · 8
PDF
Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors
2024 · Eylül Özgü, Benjamin G. Kaplan, et al. · BJC Reports · 7
PDF
PARP inhibitor combinations with high-dose vitamin C in the treatment of Ewing sarcoma: two case reports and mechanistic overview
2023 · Ashkan Adibi, Ünal Metin Tokat, et al. · Therapeutic Advances in Medical Oncology · 7
Personalized Immunotherapy Achieves Complete Response in Metastatic Adenoid Cystic Carcinoma Despite Lack of Conventional Biomarkers
2024 · Ünal Metin Tokat, Ashkan Adibi, et al. · Current Oncology · 6
PDF
Elacestrant plus alpelisib in an ESR1 and PIK3CA co-mutated and heavily pretreated metastatic breast cancer: the first case report for combination efficacy and safety
2024 · Ünal Metin Tokat, Şevval Nur Bilgiç, et al. · Therapeutic Advances in Medical Oncology · 5
Navigating uncharted territory: a case report and literature review on the remarkable response to personalized crizotinib containing combinational therapy in a pazopanib refractory patient with novel alterations
2024 · Esranur Aydın, Ünal Metin Tokat, et al. · Therapeutic Advances in Medical Oncology · 4
Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and Bevacizumab
2025 · Ashkan Adibi, Ünal Metin Tokat, et al. · Journal of Immunotherapy and Precision Oncology · 3
Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
2025 · Ünal Metin Tokat, Ashkan Adibi, et al. · Frontiers in Oncology · 2
Case report: Precision guided reactive cancer management: molecular complete response in heavily pretreated metastatic CRC by dual immunotherapy and sorafenib.
2024 · Esranur Aydın, Ünal Metin Tokat, et al. · PubMed · 2
PDF
Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory IDH2 -Mutant Cholangiocarcinoma
2025 · Eylül Özgü, Ünal Metin Tokat, et al. · JCO Precision Oncology · 1
PDF
Durable radiologic and molecular complete response following nivolumab in an HNSCC patient with UV signature and HIV
2024 · Ashkan Adibi, Ünal Metin Tokat, et al. · Oral Oncology · 1
Case Report: High TMB fails to predict immunotherapy response in PTCH1-mutant basal cell carcinoma with squamous differentiation
2026 · Esranur Aydın, Ünal Metin Tokat, et al. · Frontiers in Immunology
PDF
Pan-cancer landscape and real-world management of BRAF non-V600E and MAP2K1 alterations: Analysis from the WAYFIND-R registry.
2026 · Esranur Aydın, Ebru Karakoç, et al. · Journal of Clinical Oncology
PDF
CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report
2026 · Ünal Metin Tokat, Şevval Nur Bilgiç, et al. · Frontiers in Immunology
PDF
Erratum: Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory IDH2 -Mutant Cholangiocarcinoma
2025 · Eylül Özgü, Ünal Metin Tokat, et al. · JCO Precision Oncology
PDF
Works count: 16
Citation count: 65
H-index: 5
I10-index: 1
Year
Topic
Type